4SC AG (FRA:VSC)

Germany flag Germany · Delayed Price · Currency is EUR
0.8520
+0.0420 (5.19%)
Last updated: Sep 30, 2025, 8:04 AM CET
5.19%
Market Cap8.83M
Revenue (ttm)202.00K
Net Income (ttm)-7.68M
Shares Out10.91M
EPS (ttm)-0.70
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume11,829
Open0.8520
Previous Close0.8100
Day's Range0.8520 - 0.8520
52-Week Range0.4000 - 6.6600
Beta1.81
RSI48.42
Earnings DateOct 17, 2025

About 4SC AG

4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany and internationally. The company develops Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma. It also out-licenses and partnered drug candidates to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 13
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol VSC
Full Company Profile

Financial Performance

In 2024, 4SC AG's revenue was 345,000, an increase of 13.49% compared to the previous year's 304,000. Losses were -8.33 million, 1.18% more than in 2023.

Financial Statements

News

There is no news available yet.